GlassScriptPhysician profile
Ali Imran Saeed
NPI 1750581641
$137,845.04
in general payments reported to CMS, 2019-2025
20 companies · $39K in 2025
The $39K reported for 2025 was more than what 97% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,264 · 2020: $13.51 · 2021: $6,381 · 2022: $19K · 2023: $31K · 2024: $41K · 2025: $39K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $57K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $28K · Consulting Fee: $16K · Food and Beverage: $5,611 · Travel and Lodging: $5,481.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $56,674.99 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,550.00 |
| Consulting Fee | $16,000.00 |
| Food and Beverage | $5,611.36 |
| Travel and Lodging | $5,481.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $117,971.49 | 2021-2025 | Da Vinci Sp, Da Vinci Surgical System |
| Serpex Medical INC | $16,698.32 | 2024-2025 | |
| Pulmonx Corporation | $1,806.05 | 2019-2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter |
| Galvanize Therapeutics, INC | $237.00 | 2023-2025 | Aliya System |
| Olympus America INC. | $234.88 | 2021-2022 | |
| Astellas Pharma US INC | $174.99 | 2024 | |
| Merit Medical Systems INC | $105.73 | 2023-2025 | Elation Balloon Dilator, Endomaxx Stent and Delivery System, Aeromini Stent & Del Sys |
| Genzyme Corporation | $93.86 | 2023 | |
| Imbio INC. | $90.38 | 2023 | Imbio Lung Density Analysis |
| Actelion Pharmaceuticals US, INC. | $84.32 | 2019-2025 | Opsynvi, Uptravi |
| Medtronic, INC. | $62.49 | 2023 | Gi Genius |
| Davol INC. | $56.52 | 2023 | Phasix Mesh |
| Astrazeneca Pharmaceuticals LP | $56.24 | 2019-2024 | Airsupra |
| Pfizer INC. | $34.54 | 2020-2025 | |
| Vapotherm INC | $28.47 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Corporation of The Americas | $25.76 | 2019 | |
| Atricure, INC. | $23.72 | 2022 | |
| Portola Pharmaceuticals, LLC | $23.34 | 2019 | |
| United Therapeutics Corporation | $19.28 | 2019 | |
| Shire North American Group INC | $17.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Saeed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.